About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development of bispecific gamma delta T-cell engagers utilizing its proprietary Gammabody platform to treat tumors. Shares of the biotechnology company are skyrocketing 96% through early trading on Monday, September 26, 2022. Over the past three months, LAVA Therapeutics has seen average daily volume of 5,610 shares. However, volume of 27.29 million shares or dollar volume of around $128.81 million, has already exchanged hands through early trading.

Shares of LAVA Therapeutics are surging after the company announced that it has entered into an exclusive global license agreement with Seagen, Inc. (NASDAQ: SGEN) to further develop and commercialize LAVA-1223, a bispecific T-cell engager designed to target and activate gamma delta T-cells in solid tumors. LAVA-1223 remains a preclinical asset, which was developed using LAVA Therapeutics’ proprietary Gammabody technology.

Under the terms of the licensing agreement, Seagen will obtain an exclusive global license for the preclinical asset and will pay LAVA Therapeutics $50 million upfront. LAVA could earn up to $650 million from the deal when considering milestones and royalties. Seagen will also have the ability to exclusively negotiate rights to apply the Gammabody platform to target up to an additional two tumor targets.

“LAVA is pioneering the development of gamma delta bispecific antibodies to treat cancer, and we are pleased to work with Seagen in this pursuit. The combination of LAVA’s proprietary Gammabody platform and deep bispecific expertise, with Seagen’s leadership in developing targeted therapies for cancer and commercialization infrastructure, makes this an ideal partnership to advance novel therapies for patients,” said Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics. “This agreement enables LAVA to further validate its platform in a second solid tumor product candidate, bringing us closer toward our goal of generating effective Gammabody medicines for cancer patients. We look forward to working with Seagen to develop potential next generation cancer treatments.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223 appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.